Aarhus University Seal / Aarhus Universitets segl

Registrations of patients with renal cell carcinoma in the nationwide danish renal cancer database versus the danish cancer registry: Data quality, completeness and survival (darenca study-3)

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Bolette Danckert, Kræftens Bekæmpelse
  • ,
  • Trine Allerslev Horsbøl, Kræftens Bekæmpelse
  • ,
  • Ole Andersen, Kræftens Bekæmpelse
  • ,
  • Susanne Oksbjerg Dalton, Kræftens Bekæmpelse, Københavns Universitet
  • ,
  • Jane Christensen, Kræftens Bekæmpelse
  • ,
  • Margit Rasted, Danish Health Data Authority
  • ,
  • Astrid Petersen, Aalborg Universitet
  • ,
  • Mette Nørgaard
  • Nessn Azawi, Københavns Universitet
  • ,
  • Lars Lund, Syddansk Universitet
  • ,
  • Frede Donskov

Background: The Danish multidisciplinary renal cancer group (DaRenCa) established the nationwide database DaRenCaData in 2010. The Danish Cancer Registry (DCR) has been considered the golden standard. In contrast to DCR, DaRenCaData required the diagnosis to be histologically or cytologically verified. DaRenCaData and DCR have not previously been compared. Patients and Methods: We included patients with renal cell carcinoma registered in DaRenCaData and/or DCR from August 1st 2010 to December 31st 2015. We computed completeness and positive predictive value (PPV) of a diagnosis in DaRenCaData compared with DCR, 1-year, 3-year and 5-year mortality rate ratios, and relative survival. Results: We identified 4890 patients in the two registries. Of these, 4326 were registered in DaRenCaData and 4714 in DCR. Completeness of DaRenCaData was 88% [95% CI, 87–89%] and increased during the period from 82% to 94%. The PPV was 96% [95% CI, 95–97%]. A total of 4150 patients (85%) were found in both registries, 4% (176 patients) in DaRenCaData only, and 12% (564 patients) in DCR only. The relative survival was higher for patients in DaRenCaData vs DCR; the 1-year and 5-year relative survival was 85% vs 81% and 65% vs 59%, respectively. Compared with patients registered in both registries, the mortality rates were higher in patients registered in DaRenCaData only (1-year hazard ratio (HR)=2.84 [95% CI, 2.20–3.68]) or DCR only (1-year HR=4.29 [95% CI, 3.72–4.93]). Observed in both registries, survival improved over time with a 7% yearly reduction in death based on estimations of 1-year mortality rate ratios. Conclusion: DaRenCaData had high and increasing completeness and high PPV, establishing it as a high-quality research database. Observed in both registries, renal cell carcinoma mortality declined over time; patients only registered in DCR or DaRenCaData had poorer outcomes. This study points to the importance of assessing the inclusion criteria when interpreting registry-based studies.

OriginalsprogEngelsk
TidsskriftClinical epidemiology
Vol/bind12
Sider (fra-til)807-814
Antal sider8
ISSN1179-1349
DOI
StatusUdgivet - jul. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 194859239